MARKET

CRDF

CRDF

Cardiff Oncology Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.71
+0.60
+7.40%
After Hours: 8.70 -0.01 -0.11% 19:59 09/18 EDT
OPEN
8.47
PREV CLOSE
8.11
HIGH
9.10
LOW
8.08
VOLUME
6.42M
TURNOVER
--
52 WEEK HIGH
11.18
52 WEEK LOW
0.7010
MARKET CAP
202.31M
P/E (TTM)
-4.1031
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile

Analyst Price Target

The average CRDF stock price target is 18.50 with a high estimate of 23.00 and a low estimate of 14.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CRDF
Cardiff Oncology Inc., formerly Trovagene, Inc., is a clinical-stage biotechnology company. The Company is focused on developing treatment options for cancer patients. It is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). Its programs include the development of onvansertib in a Phase-I b/2 study of onvansertib in combination with FOLFIRI/Avastin in mCRC; a Phase II study of onvansertib in combination with Zytiga (abiraterone)/prednisone in Zytiga-resistant mCRPC, and a Phase-II study of onvansertib in combination with decitabine in AML.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Cardiff Oncology Inc stock information, including NASDAQ:CRDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRDF stock methods without spending real money on the virtual paper trading platform.